The use of neuroimaging techniques in the early and differential diagnosis of dementia
L Chouliaras, JT O'Brien - Molecular Psychiatry, 2023 - nature.com
Dementia is a leading cause of disability and death worldwide. At present there is no
disease modifying treatment for any of the most common types of dementia such as …
disease modifying treatment for any of the most common types of dementia such as …
Brain [F-18] FDG PET for clinical dementia workup: differential diagnosis of Alzheimer's disease and other types of dementing disorders
PET imaging with [F-18] FDG has been used extensively for research and clinical
applications in dementia. In the brain,[F-18] FDG accumulates around synapses and …
applications in dementia. In the brain,[F-18] FDG accumulates around synapses and …
3D conditional generative adversarial networks for high-quality PET image estimation at low dose
Positron emission tomography (PET) is a widely used imaging modality, providing insight
into both the biochemical and physiological processes of human body. Usually, a full dose …
into both the biochemical and physiological processes of human body. Usually, a full dose …
The who, when, why, and how of PET amyloid imaging in management of Alzheimer's disease—Review of literature and interesting images
S Suppiah, MA Didier, S Vinjamuri - Diagnostics, 2019 - mdpi.com
Amyloid imaging using positron emission tomography (PET) has an emerging role in the
management of Alzheimer's disease (AD). The basis of this imaging is grounded on the fact …
management of Alzheimer's disease (AD). The basis of this imaging is grounded on the fact …
Imaging of tau pathology in neurodegenerative diseases: an update
L Beyer, M Brendel - Seminars in nuclear medicine, 2021 - Elsevier
Pathological accumulated misfolded tau underlies various neurodegenerative diseases and
associated clinical syndromes. To diagnose those diseases reliable before death or even at …
associated clinical syndromes. To diagnose those diseases reliable before death or even at …
Assessment of perfusion deficit with early phases of [18F]PI-2620 tau-PET versus [18F]flutemetamol-amyloid-PET recordings
F Völter, L Beyer, F Eckenweber, M Scheifele… - European journal of …, 2023 - Springer
Purpose Characteristic features of amyloid-PET (A), tau-PET (T), and FDG-PET (N) can
serve for the A/T/N classification of neurodegenerative diseases. Recent studies showed …
serve for the A/T/N classification of neurodegenerative diseases. Recent studies showed …
Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury
L Beyer, A Nitschmann, H Barthel… - European journal of …, 2020 - Springer
Purpose Second-generation tau radiotracers for use with positron emission tomography
(PET) have been developed for visualization of tau deposits in vivo. For several β-amyloid …
(PET) have been developed for visualization of tau deposits in vivo. For several β-amyloid …
Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome
S Katzdobler, A Nitschmann, H Barthel… - European journal of …, 2023 - Springer
Abstract Purpose Early after [18F] PI-2620 PET tracer administration, perfusion imaging has
potential for regional assessment of neuronal injury in neurodegenerative diseases. This is …
potential for regional assessment of neuronal injury in neurodegenerative diseases. This is …
Classification-aided high-quality PET image synthesis via bidirectional contrastive GAN with shared information maximization
Positron emission tomography (PET) is a pervasively adopted nuclear imaging technique,
however, its inherent tracer radiation inevitably causes potential health hazards to patients …
however, its inherent tracer radiation inevitably causes potential health hazards to patients …
[HTML][HTML] The use, standardization, and interpretation of brain imaging data in clinical trials of neurodegenerative disorders
AJ Schwarz - Neurotherapeutics, 2021 - Elsevier
Imaging biomarkers play a wide-ranging role in clinical trials for neurological disorders. This
includes selecting the appropriate trial participants, establishing target engagement and …
includes selecting the appropriate trial participants, establishing target engagement and …